Alfonso
Soto Gonzalez
Eli Lilly and Company
Indianapolis, EE. UU.Publicacións en colaboración con investigadores/as de Eli Lilly and Company (1)
2021
-
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824